Dual biologics therapy in a patient with severe asthma and chronic urticaria: a case report and review of the literature

Can Bostan, Ozge; Karakaya, Gul; Kalyoncu, Ali Fuat; Damadoglu, Ebru

doi:10.1080/02770903.2023.2260884

Cited by 1 publication

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the group of patients with severe asthma and insufficiently controlled typical T2-comorbidities, a dual biologic therapy was administered in the majority of cases for the treatment of CRSwNP, CSU, and AD [33][34][35][36][37][38][39][40][41], in 1 case for EoE [42], and in 3 cases for ABPA [43][44][45]. Many combinations of biologic agents have been described.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of Biological Therapy in Severe Asthma: Where We Are?

Carriera,

Fantò,

Martini

et al. 2023

JPM

View full text Add to dashboard Cite

Biological drugs have revolutionized the management of severe asthma. However, a variable number of patients remain uncontrolled or only partially controlled even after the appropriate administration of a biologic agent. The combination of two biologics may target different inflammatory pathways, and it has been used in patients suffering from uncontrolled severe asthma with evidence of both allergic and eosinophilic phenotypes or severe asthma and type2 comorbidities. Combination therapy has also been used to handle anti-IL4/13R induced hypereosinophilia. There is insufficient data on combining biologics for the treatment of severe uncontrolled asthma and type 2 comorbidities, also because of the high cost, and currently no guideline recommends dual biologic therapy. A systematic search was performed using the Medline and Scopus databases. Published data on concurrent administration of two biological drugs in severe, uncontrolled asthma patients has been reported in 28 real-world studies and 1 clinical trial. Data extraction was followed by a descriptive and narrative synthesis of the findings. Future studies should be conducted to further assess the safety, efficacy, and cost-effectiveness of this therapeutic strategy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, a case report [40] described how a patient with severe asthma and urticaria, both uncontrolled with biologic monotherapy, was successfully treated with a combination of omalizumab and mepolizumab. No adverse events were observed after 6 months of follow-up.…”

Section: Dual Biologic Therapy For Severe Asthma and Type 2 Comorbidi...mentioning

confidence: 99%